fbpx

YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Visa Releases Strong Q4 Boosted By Robust Payments Volume – $V $DIA $INVO

By John F. Heerdink, Jr.

As per reports, Visa’s (V) fourth quarter payments volume increased 10% year over year and the number of processed transactions rose 12%. The company’s cross-border volume leapt 36% as international transaction revenue jumped 52% to $2.87 billion. The company’s first quarter fiscal 2023 earnings and revenue rose for the seventh straight quarter, with adjusted earnings jumping 21% to $2.18 per share on 12% revenue growth to $7.9 billion. Market anticipated an 11% earnings increase to $2.01 per share on 9% revenue growth to $7.7 billion.

Quarter Highlights:

  • Total payments volume increased 7% year-over-year and the company’s cross-border volume leapt 22% for the first quarter.
  • Services revenue witnessed growth by 10% to $3.5 billion.
  • Data processing revenue climbed 6% to $3.8 billion.
  • International transaction revenues saw rise by 29% to $2.8 billion.


Visa Inc. (NYSE: V) is the world’s leader in digital payments. Its mission is to connect the world through the most innovative, reliable, and secure payment network – enabling individuals, businesses, and economies to thrive.  Their advanced global processing network, VisaNet, provides secure and reliable payments around the world and is capable of handling more than 65,000 transaction messages a second. The company’s relentless focus on innovation is a catalyst for the rapid growth of connected commerce on any device, and a driving force behind the dream of a cashless future for everyone, everywhere. As the world moves from analog to digital, Visa is applying its brand, products, people, network, and scale to reshape the future of commerce. To learn more about Visa (V) and to track its ongoing progress please visit the Vista Partners Visa (V) Coverage Page.)



DID YOU KNOW?

Fertility rates have hit a record low in the United States. The latest US government fertility statistics come from 2019, and they estimate there were 58.2 births year per 1,000 women of childbearing age (defined by the CDC as women between ages 15 and 44).

If you have ever struggled with infertility issues, or know someone who has, you are probably well aware of how demoralizing it can be. Imagine for a moment spending thousands of dollars and months of intensive medical procedure only to end up empty handed, exhausted, sad, and defeated because after all of that time, work, and money, you still don’t have a baby. That’s an incredibly difficult situation, and it’s becoming more common each passing year. Likewise, the need for more effective, less invasive infertility treatment options is increasing with each passing year. This is the sole focus of medtech company INVO Bioscience (NASDAQ: INVO). Learn more by reading the following story that we published recently. 

INVO Bioscience (NASDAQ: $INVO), A Company Seeking To Address A Massively Underserved Fertility Market




Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also provides select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives. 

 

Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.

(Read Original Story: Visa, Mastercard Beat Earnings Despite Inflation-Recession Crunch in Investor's Business Daily)


YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us